Kalydeco, Vertex's CF drug, failed to show any significant improvement in the third stage trial in patients with a particular CF mutation. This was reported yesterday. It certainly does not portend bad news for INSM, and possibly helped with today's SP increase.
yous got visions of grandeur,There are many forms of CF.Da FDA has already approved Kalydeco for bouts 10% of pop-ulation.Even though the trial fail primary,it hit on many other areas of the trial,so what Vertex is doing is slowly getting the CF market. I think FDA let them file.you make it sound like CF is all arikace shows you no know not.Arikace for CF be small amount of monee for Insmeed.